CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Ejection Fraction Pros and Cons: JACC State-of-the-Art Review Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction AIM2-driven inflammasome activation in heart failure Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Clinical Trial2018 Apr 12;378(15):1386-1395.

JOURNAL:N Engl J Med. Article Link

Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure

Mehra MR, Goldstein DJ, MOMENTUM 3 Investigators. Keywords: Magnetically Levitated Left Ventricular Assist Device; heart failure; pump thrombosis;

FULL TEXT PDF